Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Kerendia Earns FDA Approval for CKD in Type 1 Diabetes

17 September 2026 · By · Wire by Fusion42

Published

17 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at empr.com →

◆ Verified

Fusion42 · 17 September 2026 · Fusion42 review

The FDA approved Kerendia (finerenone) to reduce urinary albumin-to-creatinine ratio in adults with chronic kidney disease (CKD) linked to type 1 diabetes, aiming to slow kidney function decline and progression to end-stage kidney disease.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 17 Sep 2026 and 18 Sep 2026.

◆ ◆ The Wire takeaway

You now have a new FDA approved drug option to address chronic kidney disease progression in type 1 diabetes. This opens a fresh pathway to treat a long-neglected patient group and could shift how therapies get positioned in diabetic kidney care.

◆ Coverage

3 sources · first reported 17 Sep 2026 · latest 18 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalckdtype-1-diabetesfinerenonekidney-disease